02105.HK
Laekna, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 7.19
+4.66%Sep 1, 2026, 00:22 UTC
Laekna Healthcare initiated a Phase I clinical study of LAE118 for advanced solid tumors in China and enrolled the first subject.
Source:Aug 25, 2026, 17:43 UTC
Laekna Inc. reported interim results for the six months ended June 2026, with revenue of RMB 150 million and a net loss narrowed to RMB 2.55 million from RMB 130 million a year earlier, with no dividend declared.
Source:Aug 17, 2026, 01:27 UTC
Laekna (02105.HK) issued a profit alert, expecting revenue of RMB 145-155 million for the six months ending June 30, 2026, compared to zero in the prior year period, and a net loss of no more than RMB 5 million, a 96% reduction from RMB 130 million a year earlier.
Source:Aug 12, 2026, 00:44 UTC
Laekna announced that its new drug application for LAE002 (afuresertib) has been accepted by China's National Medical Products Administration for review, for treating HR+/HER2- locally advanced or metastatic breast cancer patients with PIK3CA/AKT1/PTEN alterations.